Cost-efficacy of adalimumab, etanercept, infliximab and ustekinumab for moderate-to-severe plaque psoriasis
Journal of the European Academy of Dermatology and Venereology, 06/01/2012
Clinical Article
Ferrándiz C et al. – In terms of cost–efficacy, the most efficient biological drug was adalimumab. The robustness of this finding was confirmed by sensitivity analysis.



